Ascendis Pharma A/S Weighted Average Exercise Price Of Other Equity Instruments Granted In Share-based Payment Arrangement2019
Ascendis Pharma A/S (ASND) reported Weighted Average Exercise Price Of Other Equity Instruments Granted In Share-based Payment Arrangement2019 of 69.97 EUR/shares for the 12-month period ending 2020-12-31, per its 20-F filed 2021-03-10.
Discontinued › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019 · last filed 2021-03-10
| Period end | Weighted Average Exercise Price Of Other Equity Instruments Granted In Share-based Payment Arrangement2019 12 month |
|---|---|
| 2020-12-31 | 69.97 EUR/shares 20-F · filed 2021-03-10 |